1/16 After finishing my @UTMDAnderson residency, I've been reflecting on what I wish someone had told me as a new PGY2. These are the five lessons I'll carry into faculty—and the ones I'll share with every future resident. #MedEd #RadOnc

One of my favorite things about Paul Brown’s tweets (other than their high clinical impact of course!) is the classic blue background and yellow text which is a known sign of brilliance and old school awesomeness

PAM50 luminal B tumors need RT+ADT. The others generally do well with RT alone for BCR after RP 🎉👏🏼 Another @felixfengmd legacy ❤️ @Sophia_KamranMD @HimanshuNagarMD @NRGonc @davidjeinstein @DrRanaMcKay @alison_tree @urotoday @OncoAlert @PCF_Science @ASTRO_org #ASTRO26

A national search for a new #radonc DH and Chair @UTMDAnderson is underway. Please consider joining us in our mission to #EndCancer. See posting below: jobs.mdanderson.org/search/j…

Our Dr. Clifton Fuller has been recognized by @ASTRO_org with the 2026 Mentorship Award, which honors mentors in radiation oncology who demonstrate outstanding commitment to the professional development of clinicians, educators and researchers. #ASTRO26 #EndCancer

Congratulations to our Dr. Chelsea Pinnix on being named a 2026 @ASTRO_org fellow! She is recognized for her contributions to the field of radiation oncology. Learn more about UT MD Anderson's presence at #ASTRO26: spr.ly/6018BGguXi #EndCancer

The Daughter and Physician in the Room: I wrote this during a moment of darkness, originally for my eyes only. I’m sharing it because I know I’m not alone in these experiences and perhaps, some readers will recognize a part of your own story in mine. 🔗 tinyurl.com/3vpmj9td

Congratulations to ASTRO President Neha Vapiwala, MD, FASTRO, for being one of OncoDaily’s 100 Influential Women in Oncology. This recognition exemplifies Dr. Vapiwala’s work to communicate radiation oncology’s vital role in cancer care, and we look forward to her #ASTRO26 Presidential Symposium on Sunday, Sept. 27 at 8:15AM & her Presidential Address on Monday, Sept. 28 at 1PM. @NehaVapiwala

Now published in Practical Radiation Oncology: @ASTRO_org's first clinical practice guideline on radiation therapy for bladder cancer! The guideline supports trimodal therapy as a curative, bladder-preserving option for appropriately selected patients with muscle-invasive bladder cancer and clarifies radiation’s role after surgery and in advanced disease. Multidisciplinary care and shared decision-making are central throughout. It was a privilege to co-chair this effort with Leslie Ballas and work with an exceptional multidisciplinary task force, our patient representative, and ASTRO staff. Thank you all for your expertise, collaboration, and dedication to improving bladder cancer care. A tremendous team effort! Read more: bit.ly/4rcR77D @ESTRO_RT @Uroweb #RadiationOncology #BladderCancer #OncoNews #RadOnc #PracticalRO #GUOncology

New era @UTMDAnderson with @d_shapiro1 first clinic. Looking forward to continued, and now same day, Friday multidisciplinary management of @KidneyCancer with @PavlosMsaouel

Need to take a break from scientific sessions at @ASTRO_org?! Join us on Sun for this fun and informative session on financial planning! 💰📈 Submit anonymous questions here: docs.google.com/forms/d/e/1F…

Seminars in Radiation Oncology @ElsevierConnect is pleased to share "Medical Emergencies During Radiation Therapy" by Drs: Miriam Lane, Matthew Farrell, John Hegde @UofCalifornia sciencedirect.com/science/ar…

Nearly 20 years ago, Dr. Emma Fields walked into her first radiation oncology elective expecting a dark room and tumors. What she found instead helped set the course for her career. In recognition of Women in Medicine Month, Dr. Fields reflects on the women who showed her what leadership could look like and the friendships that continue to sustain her. She also shares why there is no single blueprint for building a meaningful career in medicine. Read her inspiring story: acro.org/news/734767/ #WomeninMedicine #RadiationOncology #Leadership

8 YEARS later, and the ADAURA curves are still speaking. In resected EGFR+ NSCLC, adjuvant osimertinib continues to show a durable OS benefit: ▫️Stage II–IIIA: 74% v 58% 8-year OS (HR 0.53) ▫️Stage IB–IIIA: 79% vs 64% (HR 0.52) Long-term follow-up matters. #WCLC26 @IASLC

Phase III randomized study PCI vs MRI alone in small cell lung cancer showed improvement cognitive failure free survival with MRI alone. Preliminary OS appears similar, pending final analysis. The authors conclude that MRI alone is preferred for small cell lung cancer, including both limited and extensive stage.

I thoroughly enjoyed reading this recently published article led by @TroyKleberMD. It pulls back the curtain on how the largest cancer center in the US selects and manages patients with stage III NSCLC with induction chemoimmunotherapy. The framing is excellent, the results are unbiased, and the discussion is full of excellent pearls. The results also include a nice analysis of different RT strategies delivered after chemoimmunotherapy, including RT alone (without concurrent chemotherapy). #WCLC26 pubmed.ncbi.nlm.nih.gov/4270…

Fun excuse to explain what mommy does for work as a #radonc in 2nd grade language :) @sumeethj #womeninmedicine #doctormom #dualphysician

As #WCLC26 attendees get excited for updates about novel drug combinations for stage III NSCLC before/after surgery, a reminder that the in-field progression rate after CRT is only in the SINGLE DIGITS. A statistic that needs to be on the table whenever a surgical management plan is being considered for clinical N2 disease. Particularly given the LRF rate after complex resections can be as high as 20%. @JoeChangMD @CoreyLangerMD

Every September we mark Prostate Cancer Awareness Month. This year it’s more personal for me. More than 330,000 American men this year will hear the words we did last spring when I was diagnosed with prostate cancer. By the time we found it, it had already spread to my bones. When prostate cancer is caught early, the five-year survival is close to 100%. So have the conversation with your doctor. Don’t put it off. If you're at average risk, that conversation should start around 50, and the guidelines now say screening every 2 to 4 years. If you're a Black man, start it at 45 or earlier. You are nearly 70% more likely to get this disease and 2 to 4 times more likely to die from it. Which is an outrage in the richest country in the world. If your father or your brother had prostate cancer, start the conversation at 45, and even earlier if more than one of them did. I am deeply grateful to the doctors, nurses and other medical professionals who helped to control my cancer and who continue to take such good care of me. Their skill, dedication, and compassion mean so much. The radiation treatment from last fall worked as intended, and I continue to do the things I care about, like finishing my memoir. Thank you to everyone who has reached out and continues to keep me and my family in your prayers. We appreciate every single one of you. It’s my hope and prayer that by sharing our experience and being part of this important conversation, we can help save lives. Talk to your doctors. Ask the hard questions. Do it for yourself, and do it for the people who love you. And no matter what, keep the faith. God bless you.

Radiotherapy can play an important role across the full spectrum of #ProstateCancer, from early-stage to more advanced disease. This #ProstateCancerAwarenessMonth, I hope more men talk with their doctors about their individual risk & potential options. Every treatment decision is personal. Grateful for all of the scientific research that provides us the evidence & clinical guidelines to tailor care for each cancer patient, every day. @PCFnews @ASTRO_org @ASCO @Movember @WorldRTDay @AmericanCancer @AACR

Wow. As an early-career oncologist, one of the biggest surprises has been just how much of patient care happens outside the exam room. 1 patient message 👉🏽 ~7 internal messages!! We need to talk more about how we build systems that recognize, and support, this ‘invisible work.’